SUMO2
Basic information
Region (hg38): 17:75165586-75182959
Previous symbols: [ "SMT3H2" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SUMO2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 0 | |||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 1 | |||||
Total | 0 | 0 | 0 | 0 | 1 |
Variants in SUMO2
This is a list of pathogenic ClinVar variants found in the SUMO2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
17-75182862-C-T | Benign (May 18, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SUMO2 | protein_coding | protein_coding | ENST00000420826 | 4 | 15671 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.869 | 0.129 | 0 | 0 | 0 | 0 | 0.00 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.20 | 6 | 49.7 | 0.121 | 0.00000253 | 631 |
Missense in Polyphen | 0 | 2.5838 | 0 | 45 | ||
Synonymous | -0.0721 | 19 | 18.6 | 1.02 | 0.00000114 | 159 |
Loss of Function | 2.39 | 0 | 6.65 | 0.00 | 4.37e-7 | 70 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00 | 0.00 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Ubiquitin-like protein that can be covalently attached to proteins as a monomer or as a lysine-linked polymer. Covalent attachment via an isopeptide bond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by an E3 ligase such as PIAS1-4, RANBP2, CBX4 or ZNF451 (PubMed:26524494). This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Polymeric SUMO2 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins (PubMed:18408734, PubMed:18538659, PubMed:21965678, PubMed:9556629). Plays a role in the regulation of sumoylation status of SETX (PubMed:24105744). {ECO:0000269|PubMed:18408734, ECO:0000269|PubMed:18538659, ECO:0000269|PubMed:21965678, ECO:0000269|PubMed:24105744, ECO:0000269|PubMed:26524494, ECO:0000269|PubMed:9556629}.;
- Pathway
- RNA transport - Homo sapiens (human);Fluid shear stress and atherosclerosis - Homo sapiens (human);HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA);DNA Repair;DNA Double-Strand Break Repair;Metabolism of lipids;SUMO is conjugated to E1 (UBA2:SAE1);SUMO is transferred from E1 to E2 (UBE2I, UBC9);SUMO is proteolytically processed;SUMOylation of DNA damage response and repair proteins;SUMOylation of transcription factors;Homology Directed Repair;SUMOylation of chromatin organization proteins;SUMOylation of RNA binding proteins;Post-translational protein modification;SUMOylation of DNA replication proteins;SUMO E3 ligases SUMOylate target proteins;basic mechanisms of sumoylation;Metabolism of proteins;Metabolism;Processing and activation of SUMO;Metabolism of steroids;SUMOylation;Vitamin D (calciferol) metabolism;Glucocorticoid receptor regulatory network;Formation of Incision Complex in GG-NER;Global Genome Nucleotide Excision Repair (GG-NER);Processing of DNA double-strand break ends;Nucleotide Excision Repair;Steroid hormones
(Consensus)
Intolerance Scores
- loftool
- rvis_EVS
- 0.17
- rvis_percentile_EVS
- 65.04
Haploinsufficiency Scores
- pHI
- hipred
- Y
- hipred_score
- 0.746
- ghis
- 0.632
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.914
Mouse Genome Informatics
- Gene name
- Sumo2
- Phenotype
- growth/size/body region phenotype; cellular phenotype; embryo phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan);
Gene ontology
- Biological process
- protein sumoylation;positive regulation of proteasomal ubiquitin-dependent protein catabolic process;positive regulation of transcription by RNA polymerase II
- Cellular component
- nucleus;nucleoplasm;PML body
- Molecular function
- transcription corepressor binding;RNA binding;protein binding;SUMO transferase activity;protein tag;ubiquitin protein ligase binding;ubiquitin-like protein ligase binding